

Appendix 4: Supplementary tables [posted as supplied by author]

Table A. Covariates included in multivariate Cox proportional hazard models for studies reporting adjusted hazard ratios.

Study	Factors included as covariates in model		
	Demographic	Clinical	Comorbidity
Abern ³⁷	Age at diagnosis Race Year of diagnosis Geographic region	Prostate Ca grade Follow-up duration	
Baxter ³⁸	Age at diagnosis Race Year of diagnosis Geographic region		
Bhojani ³⁹	Age at diagnosis Year of treatment		Charlson Comorbidity Index
Boorjian ⁴⁰	Age at diagnosis Race Education Income Relationship status	Pre-operative PSA level Biopsy Gleason score Clinical stage D'Amico risk group	Hypertension Heart disease Diabetes Stroke history Lung disease Smoking status Cardiovascular comorbidity Body mass index
Hinnen ⁴²	Age at diagnosis		
Huang ³⁴	Age at diagnosis	Follow-up duration	
Singh (2010) ⁴⁷	Age at diagnosis Race	Tumor grade	

Notes: PSA = prostate-specific antigen

Table B. Newcastle-Ottawa Scale for risk of bias assessment of studies included in the meta-analysis

Study	Selection				Comparability	Outcome			Overall
	Representativeness of exposed cohort	Selection of non-exposed	Ascertainment of exposure	Outcome not present at start		Assessment of outcome	Adequate follow-up length	Adequacy of follow-up	
Abdel-Wahab ³⁶	1	1	1	1	2	1	0	0	7
Abern ³⁷	1	1	1	0	1	1	1	0	6
Baxter ³⁸	1	1	1	1	2	1	1	0	8
Berrington de Gonzales ⁷	1	1	1	1	2	1	1	0	8
Bhojani ³⁹	1	1	1	0	2	1	0	0	6
Boorjian ⁴⁰	1	1	1	0	2	1	0	0	6
Brenner ⁸	1	1	1	1	2	1	1	0	8
Davis ⁴¹	1	1	1	0	1	1	1	0	6
Hinnen ⁴²	1	1	1	0	1	1	1	0	6
Huang ³⁴	1	0	1	0	1	1	1	0	5
Huo ⁴³	1	1	1	1	2	1	1	0	8
Margel ³³	1	1	1	1	1	1	1	0	7
Moon ⁴⁴	1	1	1	1	2	1	1	0	8
Nam ⁶	1	1	1	0	2	1	1	0	7
Nieder ⁴⁵	1	1	1	1	2	1	0	0	7
Pickles ³²	1	1	1	1	1	1	0	0	6
Rapiti ⁴⁶	1	1	1	1	2	1	1	1	9
Singh (2008) ³⁵	1	1	1	0	2	1	1	0	7
Singh (2010) ⁴⁷	1	1	1	1	2	1	1	0	8
Van Hemelrijck ⁴⁸	1	1	1	1	2	1	0	1	8
Zelevsky ¹⁰	1	1	1	0	1	1	1	1	7

Table C. Absolute difference in secondary cancer per 100 patients, stratified by radiotherapy modality and comparator group (95% confidence interval).

	Any lag	5 year lag	10 year lag
BLADDER CANCER			
Any XRT vs no XRT	0.4 (0.0 – 0.7)	0.1 (0.0 – 0.2)	0.6 (0.5 – 0.7)
EBRT vs no XRT	0.2 (-0.2 – 0.6)	0.1 (0.0 – 0.2)	0.6 (0.5-0.7)
Brach vs no XRT	0.0 (-0.2 – 0.3)	0.4 (0.2 – 0.6)	N/A
COLORECTAL CANCER			
Any XRT vs surgery	0.3 (-0.2 – 0.7)	0.1 (-0.2 – 0.4)	0.4 (0.1 – 0.7)
EBRT vs surgery	0.3 (-0.4 – 1.0)	0.1 (-0.2 – 0.4)	0.4 (0.1 – 0.7)
Brach vs surgery	0.0 (-0.4 – 0.4)	N/A	N/A
RECTAL CANCER			
Any XRT vs no XRT	0.5 (0.3 – 0.8)	0.4 (0.2 – 0.6)	0.4 (0.4 – 0.5)
EBRT vs no XRT	0.7 (0.3 – 1.0)	0.4 (0.2 – 0.6)	0.4 (0.4 – 0.5)
Brach vs no XRT	0.3 (-0.5 – 1.1)	1.4 (0.8 – 2.7)	N/A
LUNG CANCER			
Any XRT vs surgery	0.2 (0.1 – 0.3)	0.2 (0.1 – 0.3)	0.3 (0.1 – 0.5)
EBRT vs surgery	0.2 (0.1 – 0.3)	0.2 (0.1 – 0.3)	0.3 (0.1 – 0.5)
Brach vs surgery	0.5 (-0.9 – 2.0)	N/A	N/A
HEMATOLOGIC CANCER			
Any XRT vs no XRT	0.2 (0.1 – 0.3)	1.0 (-0.4 – 2.3)	0.2 (0.2 – 0.3)
EBRT vs no XRT	0.2 (0.0 – 0.4)	0.3 (0.1 – 0.4)	0.2 (0.2 – 0.3)
Brach vs no XRT	-0.1 (-0.3 – 0.0)	-0.2 (-0.2 – -0.2)	N/A
BLADDER CANCER			
Any XRT vs surgery	0.2 (0.0 – 0.3)	0.2 (0.0 – 0.5)	0.3 (0.1 – 0.5)
EBRT vs surgery	0.2 (0.0 – 0.4)	0.2 (0.0 – 0.5)	0.3 (0.1 – 0.5)
Brach vs surgery	-0.2 (-0.2 – -0.2)	N/A	N/A
LUNG CANCER			
Any XRT vs no XRT	0.2 (-0.1 – 0.4)	0.2 (0.2 – 0.3)	1.1 (-0.5 – 2.6)
EBRT vs no XRT	0.2 (-0.1 – 0.5)	0.4 (0.1 – 0.7)	1.1 (-0.5 – 2.6)
Brach vs no XRT	-0.5 (-1.1 – 0.0)	-0.5 (-0.6 – -0.3)	N/A
HEMATOLOGIC CANCER			
Any XRT vs surgery	0.0 (-0.2 – 0.2)	0.4 (-0.4 – 1.2)	1.9 (1.5 – 2.3)
EBRT vs surgery	0.0 (-0.1 – 0.2)	0.4 (-0.4 – 1.2)	1.1 (-0.5 – 2.6)
Brach vs surgery	-0.9 (-1.2 – -0.6)	N/A	N/A
HEMATOLOGIC CANCER			
Any XRT vs no XRT	0.2 (0.0 – 0.3)	0.1 (0.0 – 0.1)	0.1 (0.0 – 0.1)
EBRT vs no XRT	0.2 (0.1 – 0.3)	0.1 (0.0 – 0.1)	0.1 (0.0 – 0.1)
Brach vs no XRT	0.0 (0.0 – 0.1)	-0.6 (-0.7 – -0.5)	N/A
HEMATOLOGIC CANCER			
Any XRT vs surgery	0.1 (-0.1 – 0.3)	0.1 (0.0 – 0.1)	N/A
EBRT vs surgery	0.1 (0.0 – 0.2)	0.1 (0.0 – 0.1)	N/A
Brach vs surgery	0.1 (-0.3 – 0.5)	N/A	N/A

Note: N/A = no data available for meta-analysis.